Bone resorption predicts for skeletal complications in metastatic bone disease

Area of Science:

• Oncology
• Orthopedics
• Pharmacology

Background:

• Metastatic bone disease frequently leads to skeletal complications.
• Bone resorption rate is a key factor in disease progression.
• Bisphosphonates are a common treatment for these complications.

Purpose of the Study:

• To evaluate the relationship between bone resorption rate and skeletal complications in patients with metastatic bone disease.
• To determine if urinary N-telopeptide (Ntx) levels can predict skeletal-related events.
• To assess the utility of Ntx in guiding bisphosphonate treatment.

Main Methods:

• Monthly measurement of urinary N-telopeptide (Ntx) in 121 patients with metastatic bone disease during bisphosphonate treatment.
• Recording of skeletal-related events, bone pain hospital admissions, and death.
• Correlation and multivariate logistic regression analyses of Ntx levels and clinical outcomes.

Main Results:

• A significant correlation was found between Ntx levels and skeletal-related events/death (r=0.62 for 0-3 months, r=0.46 for 4-6 months).
• Patients with baseline Ntx ≥100 nmol mmol⁻¹ creatinine had a 19.48-fold increased risk of skeletal events/death within 3 months.
• Ntx was a highly predictive factor for adverse skeletal events in multivariate analysis.

Conclusions:

• This study demonstrates a strong correlation between bone resorption rate and skeletal complications in metastatic bone disease.
• Urinary N-telopeptide is a valuable biomarker for predicting patients at high risk of skeletal complications.
• Ntx monitoring can help identify patients who will benefit most from bisphosphonate therapy.